Aspirin, acetaminophen and proton transport through phospholipid bilayers and mitochondrial membranes - PubMed (original) (raw)

. 1992 Sep 8;114(1-2):3-8.

doi: 10.1007/BF00240290.

Affiliations

• PMID: 1334228
• DOI: 10.1007/BF00240290

Aspirin, acetaminophen and proton transport through phospholipid bilayers and mitochondrial membranes

J Gutknecht. Mol Cell Biochem. 1992.

Abstract

Mechanisms of proton transport were investigated in planar phospholipid bilayer membranes exposed to aspirin (acetylsalicylic acid), acetaminophen (4-acetamidophenol), benzoic acid and three aspirin metabolites (salicylic acid, gentisic acid and salicyluric acid). The objectives were to characterize the conductances and permeabilities of these weak acids in lipid bilayer membranes and then predict their effects on mitochondrial membranes. Of the compounds tested only aspirin, benzoate and salicylate caused significant increases in membrane conductance. The conductance was due mainly to proton current at low pH and to weak acid anion current at neutral pH. Analysis of the concentration and pH dependence suggests that these weak acids act as HA-2-type proton carriers when pH approximately pK and as lipid soluble anions at neutral pH. Salicylate is much more potent than aspirin and benzoate because salicylate contains an internal hydrogen bond which delocalizes the negative charge and increases the permeability of the anion. Model calculations for mitochondria suggest that salicylate causes net H+ uptake by a cyclic process of HA influx and A- efflux. This model can explain the salicylate-induced uncoupling and swelling observed in isolated mitochondria. Since ingested aspirin breaks down rapidly to form salicylate, these results may clarify the mechanisms of aspirin toxicity in humans. The results may also help to explain why the ingestion of aspirin but not acetaminophen is associated with Reye's syndrome, a disease characterized by impaired energy metabolism and mitochondrial swelling.

PubMed Disclaimer

Similar articles

• Reye's syndrome: salicylates and mitochondrial functions.
  Martens ME, Lee CP. Martens ME, et al. Biochem Pharmacol. 1984 Sep 15;33(18):2869-76. doi: 10.1016/0006-2952(84)90209-0. Biochem Pharmacol. 1984. PMID: 6477646
• Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: implications for the pathogenesis of Reye's syndrome.
  Trost LC, Lemasters JJ. Trost LC, et al. Toxicol Appl Pharmacol. 1997 Dec;147(2):431-41. doi: 10.1006/taap.1997.8313. Toxicol Appl Pharmacol. 1997. PMID: 9439738
• Proton conductance through phospholipid bilayers: water wires or weak acids?
  Gutknecht J. Gutknecht J. J Bioenerg Biomembr. 1987 Oct;19(5):427-42. doi: 10.1007/BF00770028. J Bioenerg Biomembr. 1987. PMID: 2826410 Review.
• Proton permeation of lipid bilayers.
  Deamer DW. Deamer DW. J Bioenerg Biomembr. 1987 Oct;19(5):457-79. doi: 10.1007/BF00770030. J Bioenerg Biomembr. 1987. PMID: 2447068 Review.

Cited by

• Intracellular proton-mediated activation of TRPV3 channels accounts for the exfoliation effect of α-hydroxyl acids on keratinocytes.
  Cao X, Yang F, Zheng J, Wang K. Cao X, et al. J Biol Chem. 2012 Jul 27;287(31):25905-16. doi: 10.1074/jbc.M112.364869. Epub 2012 Jun 7. J Biol Chem. 2012. PMID: 22679014 Free PMC article.
• Salsalate Activates Skeletal Muscle Thermogenesis and Protects Mice from High-Fat Diet Induced Metabolic Dysfunction.
  Nie L, Yuan XL, Jiang KT, Jiang YH, Yuan J, Luo L, Cui SW, Sun C. Nie L, et al. EBioMedicine. 2017 Sep;23:136-145. doi: 10.1016/j.ebiom.2017.08.004. Epub 2017 Aug 4. EBioMedicine. 2017. PMID: 28801239 Free PMC article.
• Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores.
  Fontes FL, Rooker SA, Lynn-Barbe JK, Lyons MA, Crans DC, Crick DC. Fontes FL, et al. Front Mol Biosci. 2024 Feb 13;11:1350699. doi: 10.3389/fmolb.2024.1350699. eCollection 2024. Front Mol Biosci. 2024. PMID: 38414662 Free PMC article.
• Probenecid interferes with renal oxidative metabolism: a potential pitfall in its use as an inhibitor of drug transport.
  Masereeuw R, van Pelt AP, van Os SH, Willems PH, Smits P, Russel FG. Masereeuw R, et al. Br J Pharmacol. 2000 Sep;131(1):57-62. doi: 10.1038/sj.bjp.0703541. Br J Pharmacol. 2000. PMID: 10960069 Free PMC article.
• Passive Permeability of Planar Lipid Bilayers to Organic Anions.
  Ebert A, Hannesschlaeger C, Goss KU, Pohl P. Ebert A, et al. Biophys J. 2018 Nov 20;115(10):1931-1941. doi: 10.1016/j.bpj.2018.09.025. Epub 2018 Oct 2. Biophys J. 2018. PMID: 30360927 Free PMC article.

References

1. 1. Nature. 1973 May 25;243(5404):234-6 - PubMed
2. 1. J Gen Physiol. 1976 Jun;67(6):749-71 - PubMed
3. 1. Arch Biochem Biophys. 1989 Sep;273(2):449-57 - PubMed
4. 1. J Pharmacol Exp Ther. 1956 May;117(1):39-51 - PubMed
5. 1. J Pharm Sci. 1969 Jan;58(1):102-5 - PubMed

Publication types

MeSH terms

Substances